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ABSTRACT: An enantioselective total synthesis of the 
norditerpenoid alkaloid nigelladine A is described.  Stra-
tegically, the synthesis relies on a late stage C-H oxida-
tion of an advanced intermediate.  While traditional 
chemical methods failed to deliver the desired outcome, 
an engineered cytochrome P450 enzyme was employed 
to effect a chemo- and regioselective allylic C–H oxida-
tion in the presence of four oxidizable positions.  The 
enzyme variant was readily identified from a focused 
library of three enzymes, allowing for completion of the 
synthesis without the need for extensive screening. 
The field of organic synthetic chemistry has benefited 
greatly from the many recent advances in selective C–H 
functionalization.1  Indeed, chemical oxidations of C–H 
bonds are some of the most important transformations in 
synthetic chemistry because they allow for direct access 
to oxidized intermediates, without the need for synthetic 
handles or functional group interconversions.  Despite 
recent advances, there remain significant limitations 
regarding the regioselectivity of non-directed C–H oxi-
dation reactions.  We envisioned that the recently isolat-
ed norditerpenoid alkaloids nigelladines A–C (1–3) and 
pyrroloquinoline alkaloid nigellaquinomine (4) (Figure 
1)2 would present a challenging test bed to evaluate the 
viability of late-stage C–H oxidation methods. 
 
Figure 1. Structures of nigelladines A–C and nigel-
laquinomine. 
With respect to nigelladine A, we believed that late-
stage installation of the C7 ketone would offer signifi-
cant flexibility in how we chose to construct the highly 
conjugated core of alkaloid 1.  However, despite the 
abundance of chemical allylic oxidation conditions, 
there are relatively few examples of selective oxidation 
at a 2° carbon (e.g., C7) in the presence of a non-
bridging 3° carbon (e.g., C10),3 since oxidation general-
ly occurs at the position where hydrogen abstraction is 
most favorable.4  On the other hand, enzymes are well 
known to catalyze oxidation reactions with regioselec-
tivity that defies conventional trends of chemical reac-
tivity.  Despite this, enzymatic methods are often over-
looked in total synthesis efforts due to a typically narrow 
substrate scope deriving from their exceptional specifici-
ty.  Fortunately, recent progress in the field of directed 
evolution has greatly increased the viability of biocatal-
ysis in total synthesis by increasing the reactivity and 
selectivity of enzymes for non-native transformations.5,6  
Biocatalytic C–H oxidations with engineered enzymes 
thus present an alternative approach that can circumvent 
the limitations of traditional chemical oxidations.  None-
theless, even though there have been examples of the use 
of engineered enzymes for the functionalization of com-
plex molecules,7 their application in total syntheses is 
still very limited. Herein we report the first enantioselec-
tive total synthesis of tricyclic alkaloid 1, enabled by the 
selective late-stage allylic oxidation of unsaturated imine 
5 via an engineered P450 enzyme. 
 
Figure 2. Retrosynthetic analysis of nigelladine A (1). 
Retrosynthetically, we surmised that selective late-
stage allylic oxidation of 5 at C7 would be essential to 
the synthesis of enone 1.  Imine 5 could be generated by 
the cross-coupling of vinyl boronic ester 6 and bromide 
dienone 7.  Vinyl bromide 7 was envisioned to arise via 
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 annulation of enone 8, with the quaternary stereocenter 
constructed by an asymmetric allylic alkylation reaction 
from β-ketoester 9.8  With this retrosynthetic analysis, 
we recognized that the strategically planned C–H oxida-
tion would be particularly challenging due to issues of 
site selectivity.  Imine 5 contains three different allylic 
carbon centers that could be susceptible to oxidation, a 
1°, 2°, and 3°, in addition to a relatively acidic α–carbon 
adjacent to the imine.  Together, the natural product 
combined with our strategic analysis unveiled a chal-
lenging problem for selective C–H functionalization that 
would need to be addressed in a successful synthesis. 
Scheme 1. Synthesis of dienone 13 
 
In the forward direction, known enone 10 can be syn-
thesized in excellent yield through a Stork-Danheiser 
transposition from 1,3-cyclohexanedione.9,10  Unfortu-
nately, attempts to directly acylate the α-carbon of 10 
resulted in low yields due to competing self-aldol addi-
tions.  To avoid these issues, we chose to increase the 
reactivity and steric environment of the enolate by syn-
thesizing the 1,1-dimethyl hydrazone 11.11  Hydrazone 
11 was readily acylated then hydrolyzed, and the result-
ing β-ketoester was subsequently methylated, providing 
our desired asymmetric allylic alkylation substrate (9) in 
good yield (73% over 3 steps, Scheme 1).  With β-
ketoester 9 in hand, we evaluated a variety of reaction 
parameters for the key quaternary stereocenter-forming 
asymmetric allylic alkylation and determined that the 
use of (CF3)3-t-Bu-PHOX (L1)12 in 2:1 hexanes–toluene 
with Pd2(dba)3 was optimal, generating desired enone 8 
in 96% yield and 87% ee.  Standard Tsuji–Wacker oxi-
dation of enone 8 using PdCl2 and CuCl under an at-
mosphere of oxygen generated the desired ketone,13 
which subsequently underwent an aldol condensation to 
provide dienone 12 in good yield (76% yield over 2 
steps).14  Enone 12 was then selectively mono-
brominated to form vinyl bromide 7 in 83% yield on 
gram scale.15  The cross coupling of 616 and 7 was next 
evaluated for optimal reaction conditions.  Ultimately, 
we found that Buchwald’s 2nd generation precatalyst 
with XPhos (XPhos Pd G2),17 allowed for the union of 6 
and 7 in 88% yield using only a slight excess (1.1 equiv) 
of 6.  Furthermore, triene 13 provided crystals suitable 
for X-ray diffraction and allowed us to ascertain abso-
lute stereochemistry.18 
With triene 13 in hand, we turned our attention to the 
synthesis of the heterocyclic portion of the alkaloid and 
the final stages of the synthesis.  Toward that end, triene 
13 was treated with trifluoroacetic acid (TFA) in CH2Cl2 
to deprotect the amine, which spontaneously cyclized to 
form the requisite imine upon quenching with aqueous 
sodium bicarbonate (Scheme 2).  Fortuitously, upon re-
moval of the aqueous layer, treatment with silica gel 
promoted isomerization of the exocyclic olefin into the 
ring, which, after purification, afforded the TFA salt of 5 
in 75% yield (25% over 10 steps from enone 10).19  
Scheme 2. Condensation of imine 5 
 
With only an allylic oxidation separating tricycle 5 
from nigelladine A (1), we initiated a broad exploration 
of oxidation methods for installing an oxidation handle 
at the desired C7 position.  Unfortunately, the required 
site-selective C–H oxidation of 5 or the intermediate 
enone 13 proved intractable for traditional synthetic 
methods (Table 1).  While numerous conditions were 
probed on both substrates,20,21 only a limited few effect-
ed oxidation at the desired position.  These reactions 
also exhibited poor selectivity, generating an inseparable 
mixture of mono-oxidation products, along with over-
oxidized byproducts that constituted the majority of the 
product mixture.  We thus turned our attention to en-
zymes as a potential means to achieve the desired oxida-
tion. 
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 Table 1. Attempted chemical oxidationsa 
 
a See supporting information for reaction conditions and description of the 
product distribution. b Approximated by separating the products on 
UHPLC-MS and comparing ion count of the various oxidation products. c 
Remaining percent balance remaining were unidentified side products. d 
Numbers given in parentheses indicate isolated yields of the oxidized 
product. e Protection of 5 to as an N-acyl enamide results in oxidation at 
C-14. f Shortened reaction time used to observe inherent regioselectivity 
without over oxidation. g Oxidized product S14 was isolated. 
The cytochrome P450 enzyme from Bacillus mega-
terium (P450BM3) is a workhorse of protein engineering 
studies because it is soluble and self-contained, exhibits 
one of the fastest reaction rates of any P450-catalyzed 
hydroxylation (17,000 min–1 for arachidonic acid),5a and 
possesses good stability (t1/2 = 68 min at 50 °C).22  Since 
the substrate scope of the wild-type protein is mostly 
limited to long-chain fatty acids, many engineering ef-
forts have focused on expanding the substrate scope of 
P450BM3 to accept larger and more complex substrates.  
To this end, various approaches have been applied to 
develop biocatalysts derived from P450BM3 that perform 
regioselective C–H oxygenation of complex molecules 
for which the wild-type enzyme exhibits minimal activi-
ty.6c,23 However, these approaches involved extensive 
screening endeavors, often requiring high-throughput 
screening and limiting them to substrates that were read-
ily available.   
For biocatalysis to be a viable strategy for the late-
stage of a total synthesis, it is desirable to identify a syn-
thetically useful catalyst with minimal screening. Thus, 
we elected to screen a focused library of variants that 
had been previously engineered to accept large sub-
strates,23 but had otherwise never encountered substrate 
5.  To compare the catalysts, we chose to allow the reac-
tions to proceed to only low conversion and compare the 
ratio of desired to undesired oxidation products (Table 
2).  Encouragingly, wild-type P450BM3 exhibited some 
selectivity for C7, although oxidation of the isopropyl 
C–H bond was favored 1.2:1 (Table 2, entry 1).  We then 
probed a small selection of engineered variants that all 
derive from the same parent (12 mutations from 
P450BM3).  These enzymes were previously evolved for 
regioselective oxidation of methoxymethyl-protected 
glycosides, but are distinct in that different combinations 
of active-site residues have been mutated to alanine.  
The variant 2A1, in which leucine residues 75, 181, and 
437 are mutated to alanine, exhibited a worse selectivity 
compared to wild-type, favoring the isopropyl oxidation 
product, as well as an unidentified oxidation product 
(Table 2, entry 2).  The two other variants, however, ex-
hibited a reversal in selectivity, favoring oxidation at the 
desired position in excess of 2:1 (Table 2, entries 3–4).  
The best variant proved to be 8C7, which is identical to 
2A1, but lacks the L437A mutation.  This variant favors 
oxidation at the desired position in a 2.8:1 ratio (Table 2, 
entry 4). 
Table 2. Screening of focused library for allylic oxidation 
 
aSee supporting information for full list of mutations.  bApproximated by 
separating the products on UHPLC-MS and comparing ion count of C-7 
oxidation product to all other mono-oxygenation products (m/z = 286). 
See supporting information for more details. 
Since enzyme active sites are well known to bind sub-
strate enantiomers differently, we wished to test if the 
stereochemistry of 5 would affect the activity or selec-
tivity of 8C7.  Using the Pd-catalyzed alkylation, we 
obtained both enantiomers of 5, which were then en-
riched to enantiopurity by chiral preparative HPLC.  
Each enantiomer was then subjected to oxidation by cat-
alyst 8C7.  Interestingly, at both short (15 min) and long 
(12 h) reaction times, the enantiomers gave nearly iden-
tical results, although the R enantiomer exhibited a 
slightly higher initial rate by a factor of 1.3. 
Having achieved the desired regioselectivity, we then 
needed to improve the yield.  Furthermore, we wished to 
supplant the stoichiometric use of NADPH, which is 
required if oxygen is used as the terminal oxidant.  For-
tunately, we could use NADPH in catalytic amounts by 
regenerating it in situ with an alcohol dehydrogenase 
(ADH) and isopropanol as the terminal reductant.24  
With these new conditions, we conducted the oxidation 
on a 160 mg scale, followed by subjecting the crude 
product mixture to oxidation with Dess-Martin perio-
dinane, thus affording the natural product in 21% yield 
over both steps (43% yield based on recovered 5, 
Scheme 3).  The recovered starting material (5) was 
competent in the same two-step procedure with no loss 
in efficiency (26% yield).25  Under these conditions, we 
observed up to 1700 turnovers to the C7 mono-
oxygenation product. 
 
 
 
 
 
ConditionsSubstrate HPLC Yield of Oxygenation Products (%)
b,c,d
SeO2, DCM, 40 °C
Pd/C (10 wt%), TPHP, 0 °C
SeO2, DCM, 40 °C
5
5
12
Pd/C (10 wt%), TPHP, 0 °Cf12
Cr(V) (1 equiv), MnO2
 CF3C6H5, 15-crown-5, 80 °C5
Rh2(esp)2, T-HYDRO, 23 °C5
Rh2(esp)2, T-HYDRO, 23 °C12
N
Oxidation Conditions
7
1
10
14
O
7
1
10
or
5 12
N
O
or
R'
R'''
R''
R'
R''
R'''
R' = H, OH, or t-BuOO
R'' =H, OH, t-BuOO, or O
R''' =H, OH, t-BuOO, or O
C1 C7 C10 Polyoxygenation
79 (57)e – –
26 (22) 15––
44 46
42 4
3 35g – 6
8 21(10) – 34
– 43
– 3
– 2
15 16
SM
21
5
55
2
–
7
46
–
Entry Catalysta Active-SiteAla Substitutions
Desired/
Undesiredb
1 P450BM3 – 0.86
2 2A1 L75A, L181A, L437A 0.37
3 4H5 L75A, L177A, L181A 2.1
4 8C7 L75A, L181A 2.8
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 Scheme 3. Completion of the synthesis of nigelladine Aa 
 
aADH, alcohol dehydrogenase; KPi, potassium phosphate; 
DMP, Dess-Martin periodinane. 
In summary, we have completed the first total synthe-
sis of nigelladine A in an expedient 12 steps and 5% 
overall yield (11% yield based on recovered 5).  The 
asymmetric allylic alkylation allowed for the construc-
tion of the quaternary center in high yield and enantiose-
lectivity.  Expedient identification of engineered en-
zymes allowed for a site-selective 2° allylic oxidation 
without the need for extensive generational screening or 
reaction optimization. These results demonstrate that 
enzymatic transformations are capable of defying stand-
ard chemical limitations and should be included in the 
repertoire of reactions that are traditionally considered 
for the late stages of total syntheses.  
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